Robert Mayer, PhD Novartis

Robert Mayer, Ph.D., has completed his Ph.D. at the University of Innsbruck in the field of analytical chemistry. After completion, he joined Sandoz GmbH in 2009 in the position as laboratory head in the working group for protein characterization. Since 2010 Robert Mayer has been the responsible project analyst for different biosimilar products, such as GP2015, which was approved by the FDA, EMA and other health agencies as a biosimilar to Enbrel®.